The invention relates to an implant derived from intestinal tissue and to an improved method for producing an implant from intestinal tissue. According to the invention, intestinal tissue comprising a tubular segment of intestine with at least part of its associated vasculature intact is processed by: perfusing the vasculature through a vessel thereof with at least one decellularizing medium; and separately perfusing the tubular segment of intestine through its lumen with at least one decellularizing medium. The new method greatly improves tissue processing as compared with the methods previously known in the art, in which decellularization solutions were perfused into the tissue via the vasculature only, relying on diffusion to decellularize and purify the small bowel tissue. In contrast, the invention provides for separate decellularization and purification protocols for the vascular and tubular intestinal components, which are designed to optimize decellularization and purification of each of these tissue structures while preserving certain tissue-specific three-dimensional structures. The resulting scaffold is substantially decellularized and provides an excellent implant for repair and regeneration of bowel tissue.

A new method for the treatment of ocular disease and injury are provided.

The methods involve the administration of a biocompatible implant, the porcine small intestinal serosa (or serous membrane), as graft/patch directly to the eye, for inducing restoration, remodeling, and repair of a tissue in a variety of injuries or conditions in the cornea, conjunctiva, and/or the eyelid due to trauma, diseases, or surgery.

A focus on graft interactions, safety profile has been fully defined and the membrane is reasonable in process, easy and convenient to prepare and significant in therapeutic effect.

A simple standardized and straightforward method it has been developed to fabricate this ultra-thin, delicate, and transparent material.

Derived from well-defined mechanical strength, the graft demonstrates consistency and flexibility than provides agile solutions for the Physician.

A prosthetic heart valve provided herein can include a porcine small intestine submucosa (P-SIS) tissue leaflet. The P-SIS tissue can include multiple stacked layers that are tensioned and cross-linked to form a material having a thickness of between 50 microns and 0.33 mm. In some cases, a prosthetic heart valve can include a plurality of leaflets secured together and retained within the expandable tubular member.

A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.

A prosthetic valve comprising a conical shaped sheet member comprising an extracellular matrix (ECM) composition, the sheet member having a plurality of ribbons projecting the sheet member proximal end, the distal ends of the ribbons being positioned proximate each other, wherein the sheet member comprises a conical shape.

A prosthetic valve comprising a conical shaped ribbon structure comprising an extracellular matrix (ECM) composition. The ribbon structure comprises a plurality of elongated ribbon members that are positioned proximate each other in a joined relationship, wherein the ribbon members are positioned adjacent each other and form a plurality of fluid flow modulating regions that open when fluid flow through the valve exhibits a negative flow pressure and open when fluid flow through the valve exhibits a positive flow pressure.

Provided are systems for applying a polymer fiber matrix to a tubular conduit to create a graft device. The system comprises a polymer solution comprising at least one polymer and at least one solvent; a polymer delivery assembly constructed and arranged to receive the polymer solution and to deliver the polymer fiber matrix to the tubular conduit; a rotating assembly constructed and arranged to rotate at least one of the tubular conduit or the polymer delivery assembly; and a controller constructed and arranged to control the polymer delivery assembly and the rotating assembly. The system is constructed and arranged to reduce the amount of the solvent in the graft device. Methods of applying a polymer fiber matrix with reduced solvent are also provided.

Disclosed is a method for preparing a cell growth scaffold having a structural memory feature, comprising a step of preparing a micro-fibrous or flocculent acellular tissue matrix material; a step of preparing an acidification-treated hydrogel-like acellular tissue matrix particles; proportionally mixing the micro-fibrous or flocculent acellular tissue matrix material with the acidification-treated hydrogel-like acellular tissue matrix particles, followed by injection-molding, freezing treatment, radiation treatment, and ultimately preparing a porous cell growth scaffold that can be stored at room temperature. The prepared cell growth scaffold is a porous cell growth scaffold that has no chemical crosslinking, and has a biological activity, a stable three-dimensional structure and a structural memory feature. The cell growth scaffold has an excellent biocompatibility and complete biodegradability, and supports the growth of cells and the growth of tissues and organs in vitro and in vivo, thereby being suitable for repair of human soft tissue traumas and defects.

A sheet structure formed from an extracellular matrix (ECM) composition that includes acellular ECM derived from small intestine submucosa (SIS) tissue, gentamicin and vancomycin. The sheet structure is configured to modulate inflammation of damaged biological tissue and induce cell and tissue proliferation, bioremodeling of the damaged biological tissue, and regeneration of new tissue and tissue structures with site-specific structural and functional properties, when the tissue structure is delivered to the damaged biological tissue.

A composite soft tissue repair material stable in repair area, includes a middle mechanical reinforcement layer containing crosslinked acellular matrix; and upper and lower layers containing non-crosslinked acellular matrix, wherein the upper and lower layers completely encapsulate the middle mechanical reinforcement layer to form a sandwich structure. The present invention combines the advantages of crosslinked acellular matrix and non-crosslinked acellular matrix, including high histocompatibility, no viscera erosion, uniform thickness of the whole material, resistance to infection, long-term mechanical stability of the repair area, et al, which has good application prospects.